Overview

The MagCapturer circulating tumor cell (CTC) separator machine is a benchtop instrument built for liquid-biopsy workflows that isolate rare tumor cells from whole blood. For laboratories and distributors the deciding factors are procurement practicalities - capital cost, lead time, installation, and after-sales service - more than clinical claims. This sourcing-focused guide covers what buyers should verify before placing a fleet-scale order.

How It Works

The system uses magnetic labeling to capture epithelial or marker-positive cells, separating the CTC fraction from the much larger red and white cell population. A magnetic field retains tagged cells while untagged components wash through, after which the enriched fraction is recovered for analysis. Throughput, capture efficiency, and recovery rate are the performance metrics buyers should benchmark against their sample volume, because these define whether one unit meets department demand.

Indications

The instrument supports research and companion-testing applications in oncology, including treatment-response monitoring and minimal-residual-disease exploration. It is a laboratory device, not a therapeutic product, so listings should describe workflow fit rather than patient outcomes. Buyers should match the configuration to their validated assay.

Dosage & Administration

As a device there is no dose; instead operators follow the manufacturer's run protocol for sample volume, reagent kits, and wash cycles. Each batch of consumables is lot-traced, and the instrument logs run parameters for quality records. Routine calibration against the supplied reference standard keeps recovery consistent across instruments in a multi-site network.

Storage & Sourcing

Procurement covers the main unit plus reagent kits and service contract; MOQ, lead time, and on-site installation are quoted per order. Validate that cold-chain handling applies to the magnetic reagent kits during transit, and confirm spare-part availability for uninterrupted operation. Mixed-instrument consolidation is available for distributors building a liquid-biopsy catalog. Distributors should also clarify training and qualification duties, since the first runs often need vendor support to pass the lab's acceptance test. Confirming spare-part lead times up front avoids unplanned downtime during high-volume seasons.

FAQ

Q: What should a buyer verify before procurement?
A: Benchmark throughput, capture efficiency, and recovery rate against your sample volume, then confirm reagent-kit supply, lead time, and the service contract.

Q: Are the reagent kits temperature sensitive in transit?
A: Yes, the magnetic reagent kits typically need cold-chain handling, so validate transit conditions and lot traceability with the supplier.

Q: Can multiple units be standardized across sites?
A: Yes, routine calibration against the reference standard keeps recovery consistent, which matters for networks running the same validated assay.